New drug talquetamab targets Hard-to-Treat myeloma in first human trial
NCT ID NCT03399799
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, 4000, Belgium
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, 28223, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
UMCU
Utrecht, 3584 CX, Netherlands
-
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talquetamab (a bispecific antibody that helps immune cells attack cancer)
What this could lead to
If successful, this could provide a new treatment option for people with multiple myeloma who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet proven to work. Side effects, including serious immune reactions, are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.